scholarly journals Skin reconstruction of the temporo parotid region

2020 ◽  
Vol 12 (4) ◽  
pp. 129-133
Author(s):  
Ivo Bedini ◽  
Lautaro Acosta ◽  
Luciano Cavalieri ◽  
Carlos Santiago Ruggeri
Keyword(s):  
Squamous Cell Carcinoma ◽  
Parotid Gland ◽  
Cell Carcinoma ◽  
Adenoid Cystic Carcinoma ◽  
Squamous Cell ◽  
Malignant Tumors ◽  
Skin Defect ◽  
Parotid Region ◽  
Skin Defects ◽  
Adenoid Cystic

bjectives: To determine the result of reconstruction with local or regional flaps of skin defects in the temporo-parotid region, after resection of malignant parotid gland and ear tumors, and to establish a reconstruction algorithm according to the size of the defect. Methods: The electronic medical records of the patients who underwent surgery for malignant tumors of the parotid gland and ear with invasion of the skin of the region, and who had reconstructions of the skin defect with local and regional flaps, were selected. The surgeries were performed by the surgical team of the Otorhinolaryngology service of the Italian hospital in Buenos Aires between 2005 and 2018. Results: Five patients were included.There were two malignant parotid gland tumors with histology of adenoid cystic carcinoma and squamous cell carcinoma, and three temporal bone tumors: squamous cell carcinoma, basal cell carcinoma in another and adenoid cystic carcinoma. The reconstructions were made with local or regional flaps. In skin defects smaller than 8cm the reconstructions were made with cervical and scalp flaps. In skin defects larger than 8cm the pectoralis major musculoctaneous flap were used. No patient had partial or total necrosis of the flaps. Conclusions: The results of the reconstructions with local and regional flaps of the skin defects caused by the resection of malignant tumors of the ear and the parotid gland were very good, since they allowed the repair of the defect with a good aesthetic result, without the need to perform grafts in the donor area and with few minor complications. In patients with advanced malignant tumors of the ear and parotid gland with infiltration of the surrounding skin, it is better to do the reconstruction with local or regional flaps due to the greater simplicity and speed of the surgical technique, similar aesthetic results and few complications.

Characteristic findings of adenoid cystic carcinoma on MR imaging and differentiation from squamous cell carcinoma

1994 ◽  
Vol 10 (2) ◽  
pp. 7-13 ◽  
Author(s):  
Tsuyoshi Sawamura ◽  
Kazuyuki Minowa ◽  
Satoru Abe ◽  
Keiichi Ohmori ◽  
Yoichiro Hosokawa ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Mr Imaging ◽  
Cell Carcinoma ◽  
Adenoid Cystic Carcinoma ◽  
Squamous Cell ◽  
Adenoid Cystic

Morphologic and Classificatory Considerations about 140 Cases of Carcinoma of the Nasopharynx

1983 ◽  
Vol 69 (4) ◽  
pp. 313-321 ◽  
Author(s):  
Leonardo Resta ◽  
Rosalia Ricco ◽  
Antonio Santangelo
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Malignant Tumors ◽  
Transitional Cell ◽  
Undifferentiated Carcinoma ◽  
Isolated Cells ◽  
Lymphoid Stroma ◽  
Adenoid Cystic ◽  
Female Rate

The morphologic aspects are reported for 140 cases of nasopharyngeal carcinoma collected from a retrospective review of malignant tumors of this region. Of 97 cases of undifferentiated carcinomas of nasopharyngeal type, 63 were composed of solid cords of epithelial cells (Régaud type), 22 showed isolated cells in a lymphoid stroma (Schmincke type), and in 12 the neoplastic cells were aligned with a fibrosarcoma-like aspect (spindle-cell type). The 36 cases of squamous cell carcinoma showed various degrees of differentiation. Of the remaining 7 cases, 3 were transitional cell carcinomas, 1 was an adenoid cystic carcinoma, and 3 were unclassifiable carcinomas. The undifferentiated carcinoma was present in all ages, with a male: female rate of 1.27:1. The squamous cell carcinomas were prevalent in males (3.5:1) and older patients. The 10-year survival rate was 30% in the group of patients with undifferentiated carcinoma, whereas patients with squamous cell carcinoma died within 4 years of the diagnosis.

scholarly journals A case of esophageal collision tumor with adenoid cystic carcinoma and squamous cell carcinoma.

1989 ◽  
Vol 22 (8) ◽  
pp. 2072-2075
Author(s):  
Hiroyuki KOBAYASHI ◽  
Norimasa YOSHIDA ◽  
Hirotaka MARUYAMA ◽  
Takehiro HACHISUKA ◽  
Toshihiro MORI ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Adenoid Cystic Carcinoma ◽  
Squamous Cell ◽  
Collision Tumor ◽  
Adenoid Cystic

scholarly journals Primary tracheal tumours: 21 years of experience at Peking Union Medical College, Beijing, China

2008 ◽  
Vol 122 (11) ◽  
pp. 1235-1240 ◽  
Author(s):  
L Zhengjaiang ◽  
T Pingzhang ◽  
Z Dechao ◽  
G Reddy-Kolanu ◽  
V Ilankovan
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Adenoid Cystic Carcinoma ◽  
Squamous Cell ◽  
Survival Rates ◽  
Distant Metastases ◽  
Treatment Method ◽  
Malignant Tumours ◽  
Medical College ◽  
Adenoid Cystic

AbstractObjectives:To review our experience of the treatment of primary tracheal tumours.Study design:All medical notes of patients with primary tracheal tumours diagnosed between 1981 and 2002 were retrospectively analysed.Results:In this period, 80 patients were diagnosed with primary tracheal malignancy, 48 males and 32 females. The median age was 48 years. Sixty-nine patients had malignant tumours, most commonly adenoid cystic carcinoma (50.7 per cent) or squamous cell carcinoma (30.4 per cent). Fifty-five patients underwent surgery, 30 of whom also received radiotherapy. Twenty-five patients received only radiotherapy. The five-year survival rate for all malignant tumours was 30.5 per cent. The five-year survival rates for adenoid cystic carcinoma and squamous cell carcinoma were 40.2 and 24.6 per cent, respectively. Local recurrence and distant metastases developed in 21 patients (30.4 per cent).Conclusion:Primary tracheal tumours are rare and mainly malignant. Surgery is the most effective treatment method. Technical advances allow for safe resection of the tumour with a safe, tension-free anastomosis.

Aberrant cytokine expression in serum of patients with adenoid cystic carcinoma and squamous cell carcinoma of the head and neck

Head & Neck ◽  
2007 ◽  
Vol 29 (5) ◽  
pp. 472-478 ◽  
Author(s):  
Thomas K. Hoffmann ◽  
Eniko Sonkoly ◽  
Bernhard Homey ◽  
Katrin Scheckenbach ◽  
Christian Gwosdz ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Adenoid Cystic Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Cytokine Expression ◽  
Adenoid Cystic

800 A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors

2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A849-A849
Author(s):  
Thomas Eigentler ◽  
Lucie Heinzerling ◽  
Jürgen Krauss ◽  
Carsten Weishaupt ◽  
Peter Mohr ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Phase I ◽  
Cell Carcinoma ◽  
Adenoid Cystic Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Dose Escalation ◽  
Single Agent ◽  
List Type ◽  
Adenoid Cystic

BackgroundCV8102 is a non-coding, non-capped RNA complexed with a carrier peptide activating the innate (via TLR7/8, RIG-I) and adaptive immune system.1 2 An ongoing phase I trial is investigating i.t. CV8102 either as a single agent or in combination with systemic anti-PD-1 antibodies in patients with advanced melanoma (MEL), squamous cell carcinoma of the skin (cSCC) or head and neck (hnSCC) and adenoid cystic carcinoma (ACC).MethodsAn open-label, cohort-based, dose escalation and expansion study in patients with advanced cutaneous melanoma (cMEL), cutaneous squamous cell carcinoma (cSCC), head and neck squamous cell carcinoma (hnSCC) or adenoid cystic carcinoma (ACC) is ongoing investigating i.t. CV8102 as single agent and in combination with anti-PD-1 antibodies.8 intratumoral injections of CV8102 are being administered initially over a 12 week period, while patients benefiting from the single agent therapy may receive further treatment. In an initial dose escalation part the maximum tolerated dose and recommended phase 2 dose for subsequent cohort expansion will be defined.ResultsAs of September 16, 2020, 29 patients have been treated with CV8102 as a single agent (25-900 µg) and 21 patients have received CV8102 (25-900 µg) in combination with anti-PD-1 antibodies. Most frequent treatment related adverse events were mild to moderate fever, fatigue, chills and headache. One patient treated at the 900 µg single agent experienced a dose limiting toxicity (G3 transaminase increase in the context of G2 cytokine release syndrome).Regression of injected and distant noninjected lesions was observed in several patients in the single agent and the anti-PD-1 combination cohorts. Updated safety and efficacy results will be presented.ConclusionsCV8102 showed an acceptable tolerability and preliminary evidence of clinical efficacy as single agent and in combination with anti-PD-1- antibodies.Trial RegistrationNCT03291002Ethics ApprovalThe study was approved by the Central Ethics Committees in Tuebingen, Germany under 785/2016AMG1, in France under 19.05.17.64111, in Barcelona, Spain under the EudraCT number.ConsentWritten informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.ReferencesZiegler A, Soldner C, Lienenklaus S, Spanier J, Trittel S, Riese P, Kramps T, Weiss S, Heidenreich R, Jasny E, Guzmán CA, Kallen KJ, Fotin-Mleczek M, Kalinke U. A new RNA-based adjuvant enhances virus-specific vaccine responses by locally triggering TLR- and RLH-dependent effects. J Immunol 2017;198(4):1595-1605. doi:10.4049/jimmunol.1601129Heidenreich R, Jasny E, Kowalczyk A, Lutz J, Probst J, Baumhof P, Scheel B, Voss S, Kallen KJ, Fotin-Mleczek M. A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile. Int J Cancer 2015 Jul 15;137(2):372-84. doi: 10.1002/ijc.29402

Sign in / Sign up

Export Citation Format

Share Document